Welcome to our dedicated page for Citius Oncology news (Ticker: CTOR), a resource for investors and traders seeking the latest updates and insights on Citius Oncology stock.
Citius Oncology, Inc. reports developments tied to its oncology-focused biopharmaceutical business and the commercialization of LYMPHIR™ (denileukin diftitox-cxdl). The company is a majority-owned subsidiary of Citius Pharmaceuticals and develops targeted oncology therapies. LYMPHIR is FDA approved for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma who have received at least one prior systemic therapy.
Recurring CTOR news includes U.S. launch updates, initial revenue and operating results, institutional adoption, payer coverage, international distribution through regional partners and Named Patient Programs, and investigator-led clinical studies involving LYMPHIR in additional oncology settings. Company updates also cover medical-affairs engagement, material agreements, shareholder voting matters, capital-structure disclosures, governance matters, and clinical or regulatory disclosures.
Citius Oncology (Nasdaq: CTOR) secured up to $36.5 million of financing to support LYMPHIR commercialization via a up to $25 million senior secured credit facility with Avenue (initial $10 million funded) and approximately $11.5 million from immediate warrant exercises. The credit facility term is 3.5 years; warrants and certain issuances are subject to stockholder approval and registration conditions.
Proceeds will fund sales force expansion, market access, medical affairs, manufacturing support, working capital, and general corporate purposes.
Citius Oncology (Nasdaq: CTOR) announced its first shipment of LYMPHIR (denileukin diftitox-cxdl) to Europe via a regional distribution partner on April 29, 2026, expanding patient access outside the United States.
LYMPHIR will be available through Named Patient Programs in specific countries under local regulations; it lacks EMA marketing authorization. The company continues U.S. commercial rollout after FDA approval in August 2024 and a December 2025 U.S. launch.
Citius Oncology (Nasdaq: CTOR) provided a commercial update on the U.S. launch of LYMPHIR for cutaneous T‑cell lymphoma on March 31, 2026. Early metrics show sequential order growth, 83% of target accounts progressing formulary review, ~135 health plans covering ~80% of lives, and no reported reimbursement denials. Clinical collaborations reported positive topline data at ASTCT 2026 and completed Phase I results at UPMC, with ongoing analyses and next‑stage discussions.
Commercial supply, international distribution agreements, and upcoming field team onboarding support continued launch expansion.
Citius Oncology (Nasdaq: CTOR) will attend the USCLC Annual Workshop on March 26, 2026 in Denver to discuss cutaneous T‑cell lymphoma (CTCL) care and clinical experience with LYMPHIR™ (denileukin diftitox‑cxdl), which the company recently launched in the U.S. The team will hold one‑on‑one meetings with CTCL specialists.
Citius Oncology (Nasdaq: CTOR) reported positive topline Phase 1 results for LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab in relapsed or refractory gynecologic cancers on March 10, 2026. In 25 evaluable patients, no unexpected safety signals or serious immune-related adverse events were observed.
The trial showed a 24% objective response rate (ORR) and a 48% clinical benefit rate (CBR) among 21 evaluable patients, and full results will be presented at an international cancer conference later this year.
Citius Oncology (Nasdaq: CTOR) reported preliminary Phase 1 topline data of LYMPHIR (E7777) given prior to commercial CD19 CAR‑T in 14 high‑risk relapsed/refractory DLBCL patients.
Key results: ORR 86% (CR 57%, PR 29%) at one month; one‑year PFS 77% (95% CI 43–92%) and OS 84% (95% CI 49–96%). LYMPHIR produced Treg depletion in nearly all patients and showed no dose‑limiting toxicities through 9 µg/kg; adverse events were manageable. Data were presented at the 2026 ASTCT/CIBMTR Tandem Meetings.
Citius Oncology (Nasdaq: CTOR) reported first reported revenue of $3.9 million from the December 2025 commercial launch of LYMPHIR (denileukin diftitox-cxdl) and provided fiscal Q1 2026 results for the quarter ended December 31, 2025. The company is now a commercial-stage oncology firm with an FDA-approved IL-2 receptor-directed therapy for relapsed or refractory Stage I–III CTCL.
Other Q1 highlights include $7.3 million cash on hand, a December registered offering that raised net proceeds of $15.1 million, R&D of $1.0 million, G&A of $2.9 million, and a net loss of $5.5 million ($(0.06) per share).
Citius Pharmaceuticals (Nasdaq: CTXR) reported first-quarter fiscal 2026 results and the first reported revenue after the December 2025 commercial launch of LYMPHIR. Consolidated revenue was $3.9 million from initial U.S. distributor sales. Cash totaled $7.7 million and the company generated approximately $20.9 million net proceeds from equity financings. R&D expense declined to $1.6 million, general and administrative expense was $5.7 million, stock-based compensation rose to $4.3 million, and net loss narrowed to $8.2 million (−16% year-over-year). The company reported early physician adoption, international named-patient agreements, and ongoing investigator-initiated studies exploring LYMPHIR combinations.
Citius Oncology (NASDAQ: CTOR) entered an exclusive distribution agreement with Uniphar to expand access to LYMPHIR™ (denileukin diftitox-cxdl) in designated territories across Western and Eastern Europe via country-specific managed access programs.
Uniphar will manage market access and distribution where permitted by local law; Citius Oncology will supply finished product and provide ongoing support. LYMPHIR is not approved for commercial use outside the United States and will be provided only through managed access programs, which do not constitute marketing authorization.
Citius Oncology (Nasdaq: CTOR) reported fiscal 2025 results and a business update following the U.S. commercial launch of LYMPHIR in December 2025 for relapsed/refractory Stage I–III CTCL after ≥1 prior systemic therapy. The company closed $36M in strategic financings (three offerings in July, Sept, Dec 2025) and received a $1M note from parent Citius Pharma to support commercialization. Cash was $3.9M as of Sept 30, 2025. FY25 R&D was $6.4M, G&A $8.8M, stock-based comp $8.3M, and net loss was $24.8M (‑$0.34/share). Company announced U.S. wholesaler agreements, 19-market named patient programs, an AI commercial collaboration, and preliminary combo trial results.